Dermatology

Latest News

Two Global Phase 3 Trials Confirm Efficacy of Rocatinlimab for People With Moderate-to-Severe Atopic Dermatitis / image credit: MJH life sciences
Two Global Phase 3 Trials Confirm Efficacy of Rocatinlimab for People With Moderate-to-Severe Atopic Dermatitis

December 11th 2025

Two global phase 3 trials found rocatinlimab significantly improved EASI-75 and vIGA-AD outcomes at 24 weeks in people with moderate-to-severe AD with acceptable safety.

New Genetic Evidence Supports a Causal Link Between Psoriasis and Depression / image credit ©Ольга Тернавская/stock.adobe.com
Genetic Evidence Supports a Causal Link Between Psoriasis and Depression

December 10th 2025

Dupilumab and Other Monoclonals Rank Highly for Moderate-to-Severe Atopic Dermatitis, Network Meta-Analysis Shows / Image credit: ©aamylya/AdobeStock
Dupilumab and Other Monoclonals Rank Highly for Moderate-to-Severe Atopic Dermatitis, Network Meta-Analysis Shows

December 9th 2025

Early Biologic Therapy for Hidradenitis Suppurativa Supported by Majority of Specialists, Survey Shows / image credit: ©syahrir/AdobeStock
Early Biologic Therapy for Hidradenitis Suppurativa Supported by Majority of Specialists, Survey Shows

December 8th 2025

Topical Roflumilast 0.3% Demonstrates Significant Efficacy Across Psoriasis Severity Measures in Updated Meta-Analysis / Image credit: ©molekuul.be/AdobeStock
Topical Roflumilast 0.3% Demonstrates Significant Efficacy Across Psoriasis Severity Measures in Updated Meta-Analysis

December 8th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.